DAWN
Day One Biopharmaceuticals, Inc. NASDAQ Listed May 27, 2021$21.53
+0.00%
vs $21.53
Mkt Cap $2.2B
52w Low $5.63
100.0% of range
52w High $21.53
50d MA $18.21
200d MA $10.72
P/E (TTM)
-20.7x
EV/EBITDA
—
P/B
5.0x
Debt/Equity
0.0x
ROE
-24.3%
P/FCF
-21.4x
RSI (14)
65.20
ATR (14)
$0.02
Beta
-1.75
50d MA
$18.21
200d MA
$10.72
Avg Volume
2.3M
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
395 Oyster Point Boulevard · Brisbane, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -0.17 | -0.20 | -17.6% | 12.02 | -9.3% | -9.1% | -2.6% | -0.5% | -2.2% | -3.3% | — |
| Nov 4, 2025 | AMC | -0.28 | -0.19 | +31.8% | 7.30 | +8.4% | +25.2% | -1.6% | +8.2% | +4.4% | +2.0% | — |
| Aug 5, 2025 | AMC | -0.35 | -0.29 | +17.1% | 6.88 | -13.5% | -15.7% | +4.0% | +1.2% | -3.3% | +4.1% | — |
| May 6, 2025 | AMC | -0.46 | -0.35 | +23.9% | 6.99 | +7.6% | -9.9% | +7.3% | -4.6% | +2.0% | -3.8% | — |
| Feb 25, 2025 | AMC | -0.35 | -0.69 | -97.1% | 11.82 | -11.9% | -16.5% | -4.4% | -4.0% | -8.9% | +4.2% | — |
| Oct 30, 2024 | AMC | -0.41 | 0.38 | +192.7% | 14.47 | +10.1% | +1.7% | -0.5% | +1.1% | +2.3% | +1.8% | — |
| Jul 30, 2024 | AMC | -0.67 | -0.05 | +92.5% | 15.19 | +0.5% | -5.8% | -1.0% | -1.8% | -4.7% | -1.1% | — |
| May 6, 2024 | AMC | -0.67 | -0.72 | -7.5% | 16.60 | +1.2% | +2.9% | -3.9% | -0.2% | -2.3% | +0.3% | — |
| Feb 26, 2024 | AMC | -0.57 | -0.64 | -12.3% | 15.65 | +0.8% | +11.1% | -3.2% | -0.6% | +4.4% | -3.3% | — |
| Nov 6, 2023 | AMC | -0.60 | -0.54 | +10.0% | 12.19 | +0.7% | +1.4% | -1.8% | -7.6% | +1.2% | +0.4% | — |
| Aug 7, 2023 | AMC | -0.60 | -0.61 | -1.7% | 12.37 | +1.6% | +5.7% | +0.2% | +3.2% | -0.4% | +0.2% | — |
| May 1, 2023 | AMC | -0.60 | -0.59 | +1.7% | 14.47 | +2.1% | -3.4% | +1.6% | -4.4% | +0.7% | -4.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | JP Morgan | Downgrade | Overweight → Neutral | — | $21.28 | $21.27 | -0.0% | -0.1% | +0.1% | +0.2% | +0.2% | -0.3% |
| Mar 10 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $21.33 | $21.28 | -0.2% | -0.2% | -0.1% | +0.1% | +0.2% | +0.2% |
| Mar 9 | Wedbush | Downgrade | Outperform → Neutral | — | $21.20 | $21.19 | -0.0% | +0.6% | -0.2% | -0.1% | +0.1% | +0.2% |
| Mar 6 | Needham | Downgrade | Buy → Hold | — | $12.78 | $21.13 | +65.3% | +65.9% | +0.6% | -0.2% | -0.1% | +0.1% |
| Mar 6 | Jones Trading | Downgrade | Buy → Hold | — | $12.78 | $21.13 | +65.3% | +65.9% | +0.6% | -0.2% | -0.1% | +0.1% |
| Feb 25 | Wedbush | Maintains | Outperform → Outperform | — | $12.02 | $10.90 | -9.3% | -9.1% | -2.6% | -0.5% | -2.2% | -3.3% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $12.02 | $10.90 | -9.3% | -9.1% | -2.6% | -0.5% | -2.2% | -3.3% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.02 | $10.90 | -9.3% | -9.1% | -2.6% | -0.5% | -2.2% | -3.3% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.52 | $8.51 | -0.1% | +4.2% | +6.2% | -0.2% | +0.9% | -7.5% |
| Nov 24 | Needham | Maintains | Buy → Buy | — | $8.52 | $8.51 | -0.1% | +4.2% | +6.2% | -0.2% | +0.9% | -7.5% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $8.99 | $9.07 | +0.9% | +8.2% | +4.4% | +2.0% | -0.2% | -14.4% |
| Nov 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.30 | $7.91 | +8.4% | +25.2% | -1.6% | +8.2% | +4.4% | +2.0% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.88 | $5.95 | -13.5% | -15.7% | +4.0% | +1.2% | -3.3% | +4.1% |
| Aug 6 | Needham | Maintains | Buy → Buy | — | $6.88 | $5.95 | -13.5% | -15.7% | +4.0% | +1.2% | -3.3% | +4.1% |
| May 7 | Needham | Maintains | Buy → Buy | — | $6.99 | $7.52 | +7.6% | -9.9% | +7.3% | -4.6% | +2.0% | -3.8% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.97 | $7.72 | -3.1% | -3.3% | -6.4% | -2.8% | -4.4% | +8.3% |
| Mar 25 | Goldman Sachs | Maintains | Buy → Buy | — | $8.31 | $8.31 | +0.0% | -0.4% | -1.9% | +0.9% | -1.5% | -1.7% |
| Mar 5 | JP Morgan | Maintains | Overweight → Overweight | — | $8.60 | $9.10 | +5.8% | +12.8% | -6.2% | -4.7% | -6.9% | +7.3% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $11.82 | $10.41 | -11.9% | -16.5% | -4.4% | -4.0% | -8.9% | +4.2% |
| Feb 26 | Wedbush | Maintains | Outperform → Outperform | — | $11.82 | $10.41 | -11.9% | -16.5% | -4.4% | -4.0% | -8.9% | +4.2% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.82 | $10.41 | -11.9% | -16.5% | -4.4% | -4.0% | -8.9% | +4.2% |
| Feb 10 | Goldman Sachs | Maintains | Buy → Buy | — | $12.05 | $12.14 | +0.7% | -1.5% | +0.4% | +1.8% | +0.7% | +0.4% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $11.80 | $11.83 | +0.3% | -2.0% | -3.5% | +6.4% | +4.5% | +1.1% |
| Jan 7 | BofA Securities | Maintains | Buy → Buy | — | $12.20 | $12.16 | -0.3% | +1.6% | -1.6% | -3.3% | -2.0% | -3.5% |
| Dec 17 | Jones Trading | Maintains | Buy → Buy | — | $12.62 | $12.44 | -1.4% | +0.2% | -0.9% | -0.6% | +2.6% | -0.8% |
| Oct 31 | Needham | Maintains | Buy → Buy | — | $14.47 | $15.93 | +10.1% | +1.7% | -0.5% | +1.1% | +2.3% | +1.8% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.47 | $15.93 | +10.1% | +1.7% | -0.5% | +1.1% | +2.3% | +1.8% |
| Oct 9 | Needham | Maintains | Buy → Buy | — | $13.69 | $13.69 | +0.0% | +2.6% | -3.7% | +2.6% | +3.0% | +3.7% |
| Aug 6 | JP Morgan | Maintains | Overweight → Overweight | — | $13.26 | $13.42 | +1.2% | -1.1% | -3.0% | +3.2% | +1.3% | +1.4% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.31 | $15.13 | +5.7% | -1.0% | -1.8% | -4.7% | -1.1% | -3.0% |
| Aug 1 | BofA Securities | Upgrade | Underperform → Buy | — | $14.31 | $15.13 | +5.7% | -1.0% | -1.8% | -4.7% | -1.1% | -3.0% |
| Aug 1 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $14.31 | $15.13 | +5.7% | -1.0% | -1.8% | -4.7% | -1.1% | -3.0% |
| Jul 31 | Needham | Maintains | Buy → Buy | — | $15.19 | $15.27 | +0.5% | -5.8% | -1.0% | -1.8% | -4.7% | -1.1% |
| Jul 30 | Needham | Maintains | Buy → Buy | — | $15.36 | $16.27 | +5.9% | -1.1% | -5.8% | -1.0% | -1.8% | -4.7% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.88 | $16.14 | +1.6% | +0.9% | -4.2% | -1.1% | -5.8% | -1.0% |
| Jul 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.71 | $14.82 | +8.1% | +8.0% | +0.5% | -1.1% | +2.7% | +0.7% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.39 | $13.33 | -0.4% | -2.0% | +4.3% | -1.1% | -1.0% | +0.3% |
| Jun 19 | Needham | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| May 7 | Needham | Maintains | Buy → Buy | — | $16.60 | $16.80 | +1.2% | +2.9% | -3.9% | -0.2% | -2.3% | +0.3% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.60 | $16.80 | +1.2% | +2.9% | -3.9% | -0.2% | -2.3% | +0.3% |
| Apr 25 | Needham | Maintains | Buy → Buy | — | $15.19 | $14.80 | -2.6% | -13.0% | +12.9% | +10.5% | +3.8% | +3.5% |
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.64 | $16.74 | +0.6% | -8.7% | -13.0% | +12.9% | +10.5% | +3.8% |
| Apr 24 | Needham | Maintains | Buy → Buy | — | $16.64 | $16.74 | +0.6% | -8.7% | -13.0% | +12.9% | +10.5% | +3.8% |
| Apr 22 | JP Morgan | Maintains | Overweight → Overweight | — | $14.96 | $15.39 | +2.9% | +2.8% | +8.2% | -8.7% | -13.0% | +12.9% |
| Mar 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.02 | $15.25 | +1.5% | +3.3% | +1.7% | +4.6% | -2.2% | -2.0% |
| Feb 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.38 | $17.18 | -1.2% | -3.2% | -0.6% | +4.4% | -3.3% | -1.2% |
| Feb 27 | Oppenheimer | Maintains | Perform → Perform | — | $15.65 | $15.77 | +0.8% | +11.1% | -3.2% | -0.6% | +4.4% | -3.3% |
| Feb 27 | Goldman Sachs | Maintains | Buy → Buy | — | $15.65 | $15.77 | +0.8% | +11.1% | -3.2% | -0.6% | +4.4% | -3.3% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $12.19 | $12.28 | +0.7% | +1.4% | -1.8% | -7.6% | +1.2% | +0.4% |
| Nov 7 | Wedbush | Maintains | Outperform → Outperform | — | $12.19 | $12.28 | +0.7% | +1.4% | -1.8% | -7.6% | +1.2% | +0.4% |
No insider trades available.
8-K
Aura Biosciences, Inc. -- 8-K Filing
Aura Biosciences appointed an experienced biopharmaceutical executive as Chief Operating Officer, bringing rare disease development expertise from Hyperion Therapeutics' successful acquisition by Horizon Pharma.
May 4
SC TO-T
!!! Very High
Day One Biopharmaceuticals, Inc. -- Tender Offer
Ajinkyotsu Pharma's tender offer for Day One Biopharmaceuticals (DAWN) will provide shareholders a liquidity event at a predetermined price, though deal terms and valuation details require further disclosure review.
Apr 23
8-K · 5.02
!!! Very High
Day One Biopharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Day One Biopharmaceuticals' tender offer expired with 85.34% of shares validly tendered, indicating substantial shareholder acceptance of the acquisition or recapitalization proposal.
Apr 23
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders have an opportunity to sell shares at a predetermined price in a tender offer, which could provide liquidity but may signal the company faces acquisition or financial challenges requiring external validation.
Apr 14
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders face a potential change of control through this tender offer, making immediate evaluation of the offer price versus intrinsic value critical for deciding whether to accept or reject.
Apr 8
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders can sell shares at a premium price through this tender offer, providing liquidity but potentially signaling an acquisition or significant corporate restructuring ahead.
Mar 26
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders have an opportunity to sell shares at a predetermined price through a tender offer, suggesting potential acquisition or restructuring that could provide liquidity or signal management's view of undervaluation.
Mar 26
8-K
Day One Biopharmaceuticals, Inc. -- 8-K Filing
Day One Biopharmaceuticals (DAWN) has completed an acquisition and filed audited financial statements for the acquired target company, signaling deal closure and integration commencement.
Mar 9
8-K
Day One Biopharmaceuticals, Inc. -- 8-K Filing
Day One Biopharmaceuticals is proceeding with a merger transaction where closing conditions have been substantially satisfied, with no material adverse effects identified affecting the deal's completion.
Mar 6
8-K · 7.01
! Medium
Day One Biopharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Day One Biopharmaceuticals secured a significant revenue opportunity by granting Ipsen exclusive commercialization rights to OJEMDA outside the U.S., expanding the drug's market reach internationally.
Mar 2
8-K · 7.01
! Medium
Day One Biopharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Day One Biopharmaceuticals updated its corporate presentation, likely signaling management's refined messaging to investors about strategy, pipeline progress, or financial outlook.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Glazer Capital, Llc | 4,683,687 | $100M | New | Mar 2026 |
| 2 | Kryger Capital Llc | 3,896,485 | $84M | New | Mar 2026 |
| 3 | Deerfield Management Company, L.p. | 3,723,131 | $80M | — | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 3,357,684 | $72M | New | Mar 2026 |
| 5 | Jpmorgan Chase & Co | 3,134,753 | $67M | Added | Mar 2026 |
| 6 | Ubs Group Ag | 2,305,123 | $49M | Added | Mar 2026 |
| 7 | Vanguard Portfolio Management Llc | 2,095,813 | $45M | New | Mar 2026 |
| 8 | Qube Research & Technologies Ltd | 1,954,552 | $42M | Added | Mar 2026 |
| 9 | Millennium Management | 1,927,557 | $41M | Added | Mar 2026 |
| 10 | Bank Of America Corp /de/ | 1,902,868 | $41M | Added | Mar 2026 |
| 11 | Nuveen, Llc | 1,823,998 | $39M | Added | Mar 2026 |
| 12 | Oddo Bhf Asset Management Sas | 1,550,000 | $33M | New | Mar 2026 |
| 13 | Soros Fund Management Llc | 1,539,100 | $33M | New | Mar 2026 |
| 14 | First Trust Capital Management L.p. | 1,496,007 | $32M | New | Mar 2026 |
| 15 | Morgan Stanley | 3,100,548 | $29M | Added | Dec 2025 |
| 16 | Pictet Asset Management Holding Sa | 2,990,801 | $28M | Added | Dec 2025 |
| 17 | Renaissance Technologies Llc | 1,296,984 | $28M | Reduced | Mar 2026 |
| 18 | Hudson Bay Capital Management Lp | 1,700,000 | $16M | Added | Dec 2025 |
| 19 | Northern Trust Corp | 666,180 | $14M | Added | Mar 2026 |
| 20 | Magnetar Financial Llc | 645,173 | $14M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.22B
Enterprise Value
$1.79B
P/E (TTM)
-20.70x
Forward P/E
—
PEG Ratio
-4.58x
P/B
5.05x
P/S
14.07x
P/FCF
-21.39x
EV/EBITDA
—
Shares Out
103.4M
Financials (TTM)
Revenue
$158.2M
Net Income
-$107.3M
EBITDA
-$105.8M
Free Cash Flow
-$104.1M
Op Cash Flow
-$103.8M
EPS Basic
$-1.04
EPS Diluted
$-1.04
EPS Forward
$-0.78
Gross Margin
89.1%
Op Margin
-80.8%
Net Margin
-67.8%
Balance Sheet
Total Assets
$507.8M
Total Liab.
$66.7M
Total Equity
$441.2M
Cash
$441.1M
LT Debt
$2.6M
Book Value/Sh
$4.27
Debt/Equity
0.01x
Current Ratio
8.02
Quick Ratio
7.91
Returns & Growth
ROE
-24.3%
ROA
-21.1%
ROIC
-28.0%
Rev Growth YoY
+20.6%
EPS Growth YoY
-2.0%
Price Returns
2W
—
1M
+0.0%
3M
+79.1%
6M
+142.5%
12M
+241.7%
Technicals
52W High
$21.53
52W Low
$5.63
50d MA
$18.21
200d MA
$10.72
RSI (14)
65.20
ATR (14)
$0.02
Beta
-1.75
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$23.75
High
$26.00
Low
$21.50
Median
$23.75
Data updated apr 25, 2026 4:39am
· Source: financialmodelingprep.com